MONTE ROSA THERAPEUTICS INC(NASDAQ:GLUE) stock News

GLUE Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected

2 days ago - By: The Motley Fool - Mentions: NVS

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

2 days ago - By: Zacks Investment Research - Mentions: IRD

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

2 days ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

2 days ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

3 days ago - By: Zacks Investment Research - Mentions: CERT

Certara, Inc. (CERT) Q2 Earnings Miss Estimates

18 days ago - By: Benzinga - Mentions: GRI IGC EQ NNVC ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

19 days ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

19 days ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

a month ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

a month ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

2 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

2 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

2 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

3 months ago - By: Zacks Investment Research - Mentions: IGMS

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

3 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

3 months ago - By: Zacks Investment Research - Mentions: TCRX

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

3 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

5 months ago - By: Benzinga - Mentions: NVS

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders

5 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

5 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

5 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

6 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

6 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

7 months ago - By: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

7 months ago - By: Monte Rosa Therapeutics, Inc.